NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of Off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-l1 Checkpoint Inhibitor Therapy

Study Tests Elimination Of Chemotherapy And Expands Upon Previous Combination Study Of NK Cell Therapy With N-803 Showing Promising Clinically Meaningful Responses In Merkel Cell Carcinoma PatientsCULVER CITY, CA  –January 9, 2019 - NantKwest Inc. (Nasdaq:NK), a...

NantCell Announces New Celgene Investment

Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7thSecond Round Crossover Funding Brings Celgene’s Investment to $105M in NantCellValued at $4 BillionCurrently Enrolling Patients in Advanced Stage Trials...